iStock_000007042359_Medium

 

Professor Christoph Huber

Christoph HubergProfessor Christoph Huber is Emeritus Professor of Medicine at the Medical School of the Johannes Gutenberg University in Mainz, co-founder and board member of the Translational Oncology research organization and co-founder and Head of Supervisory Board at the Cluster for individualized immune intervention (CI-3). From 1990 until 2009 he directed the Hematology-Oncology Department of the Johannes-Gutenberg University (JGU) in Mainz. Under his lead the department was newly built, expanded and completely restructured with a strong and internationally recognized focus on basic and applied tumor and transplantation immunology and translational research. After his studies at Medical School of the Leopold Franzens University in Innsbruck, Christoph Huber gained experience as a health professional of internal medicine and received his Ph.D. Several research scientist visits (Dept. Tumor Biology of Karolinska Institute, Stockholm, Wallenberg Laboratorium, Dept. Immunology of Uppsala University) were followed by an education in clinical bone marrow transplantation at the Fred Hutchinson Cancer Research Center, Seattle. Back in Innsbruck, Dr Huber headed the bone marrow transplantation section of the Department of Internal Medicine, becoming Professor of Clinical Immunobiology. He also co-founded the biopharmaceutical companies Ganymed Pharmaceuticals and BioNTech and serves on both of their boards.   He is a member of numerous scientific committees, in particular the international Association of Cancer Immunotherapy (CIMT), which he co-founded and chairs. Dr Huber is also scientific advisor of multiple biotech companies in Germany, UK and USA, and advisor of leading European strategic investors. He is the author of more than 250 publications, among them various articles in “Nature”, “Nature Immunology”, “Immunity”, and the “Journal of Experimental Medicine”.

 

Professor Jan Vermorken

Jan VermorkenProfessor Jan Vermorken served on the medical staff of oncology, at the University Hospital Vrije Universiteit in Amsterdam, The Netherlands, and is Emeritus Professor of Oncology at the University of Antwerp and past head of the Department of Medical Oncology at the Antwerp University Hospital in Edegem, Belgium, where he still works as a consultant.  His main field of interest is in gynecological and head & neck oncology.  In addition, he coordinated large clinical trials in breast and colon cancer, including the OncoVAX®’s Phase III trial.  His main research areas concern early clinical and pharmacological studies with new drugs, studies on the interaction of chemotherapy and radiation therapy, HPV in various malignancies and immunological approaches. Dr. Vermorken is a member of the European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group (GCG) and the EORTC Head and Neck Cancer Group (HNCG).  He chaired the EORTC-GCG from 1983 to 1989 and the EORTC-HNCG from 2006 to 2009.  He is still an active member with both groups.  He is an officer for ESMO, was a member of the ESMO executive committee during the time that he chaired the ESMO National Representative Committee (1991 – 1996) and the ESMO Education Committee (1996 – 2002) and is a prominent member of the ESMO faculty.  He is also a member of the International Gynecological Cancer Society (IGCS), was founding chair of the Gynecological Cancer Intergroup (GCIG) and was Chairman of the Belgian Association of Cancer Research (BACR) from 2003 to 2011, now still being part of its board. Dr. Vermorken is a member of six editorial boards of international journals, reviewer of 13 cancer journals and author or co-author of more than 500 publications in international journals.  Dr. Vermorken has been Editor-in-Chief of Annals of Oncology from January 2009 until January 2014. In 2013 he received the title of Commander in the Order of Leopold for his contributions to oncology.

Professor Andrew Hughes

Andrew hughesProfessor Andrew Hughes is strategy director of the experimental cancer medicine team at The Christie. This role involves overseeing the clinical contribution to Phase 1 cancer clinical trials and a strategic growth of the research by up to 10 fold over the next 5 years. Previous to that he was Global VP of early clinical development at AstraZeneca Pharmaceuticals leading over 50 research and early clinical development programmes of novel candidate drugs. He graduated with double first in medical sciences at Cambridge, spending 3 years as a Tutor in Physiology and Bye-fellow of Downing College, Cambridge, whilst completing a PhD in behavioural neuroendocrinology in the Dept. of Anatomy. He subsequently practised general clinical medicine in Manchester’s teaching hospitals in the UK, joining Zeneca in 1994 from being a registrar in Cardiology. Within industry, he has had responsibilities on the corporate pain control drug development board and in setting the limits of human exposure based on existing pre-clinical and clinical data for all development products. Since 2001 he has been accountable for the early phase clinical development of AstraZeneca’s oncology compounds, and has been clinical investigator on over 200 clinical trials. He is approved by the Resuscitation Council (UK) as a director in Advanced Cardiac Life Support, and regularly teaches health professionals in ACLS. During 2002-3 he served on the board of the Faculty of Pharmaceutical Medicine, UK; and has the responsibility for the clinical pharmacology revision module for those physicians sitting the Diploma of Pharmaceutical Medicine. He is a former member of the board of NCRI, on the editorial committee for Annals of Oncology and on the Steering Committee for the FDA Biomarkers Consortium. In 2006, he was appointed to a chair of Translational medicine at the University of Manchester, UK. He serves on CRUK’s Biomarkers evaluation research panel and MRC’s translational medicine grant awarding bodies.

 

Professor Kristian Berg

Kristian BergProfessor Kristian Berg is Head of Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, since 2010. He graduated as biochemist in 1985 at the University of Oslo where he obtained his doctoral degree (dr.philos) in experimental photomedicine in 1990. He has 30 years of experience in experimental and preclinical research within the field photodynamic therapy (PDT).  He has a broad background in developing technologies from the bench via preclinical animal-based studies to the clinic and has contributed to establish two companies currently listed on the Oslo Stock Exchange with 2 products approved for clinical use and several in pipeline. Professor Berg is an inventor of Photochemical Internalisation (PCI). He has received several prices such as Claude Rimingtons memorial prize, Pater-Leander-Fischer prize by Deutsche Gesellschaft für Lasermedizin,  Kendric C. Smith Innovation Lecture Award and European Society for Photobiology Award for Excellence in Photobiological Research. He is also an appointed Member of the Norwegian Academy of Science and Letters from 2014.  He has been President of the European Society for Photobiology (2007-2009), visiting professor at the Medical Faculty, University of Wroclaw, Poland, and professor at School of Pharmacy, University of Oslo from 2009. Professor Berg has published more than 200 papers, mainly in peer reviewed journals and is co-inventor of 8 patents.